Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denise Chang

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Implementation Research and Practice|April 24, 2023
Augmenting systems-level implementation of patient-reported outcomes for depression care through the use of structured analysis and design techniqueElizabeth J Austin, Joseph A Heim, Savitha Sangameswaran, et al.
Journal of Psychopharmacology (Oxford, England)|March 11, 2021
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar maniaEduard Vieta, Gary Sachs, Denise Chang, et al.
Acta Neuropsychiatrica|November 19, 2024
A randomised study and an extension study of brexpiprazole in patients with borderline personality disorderBrian Rothman, Claudette Brewer, Denise Chang, et al.
Expert Review of Neurotherapeutics|April 1, 2026
Centanafadine for the treatment of attention-deficit/hyperactivity disorder in adults: a plain language summary of publicationCaroline L Ward, Jessica Madera-McDonough, Mary Hobart, et al.
Journal of Clinical Psychopharmacology|July 2, 2025
52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity DisorderGregory W Mattingly, Osman Turkoglu, Denise Chang, et al.
Psychiatric Services (Washington, D.C.)|April 15, 2021
Provision of Collaborative Care Model and General Behavioral Health Integration Services in MedicareLeah M Marcotte, Ashok Reddy, Lingmei Zhou, et al.
Journal of General Internal Medicine|September 2, 2020
Transforming Population-Based Depression Care: a Quality Improvement Initiative Using Remote, Centralized Care ManagementDenise Chang, Andrew D Carlo, Sara Khor, et al.
Journal of Clinical Psychopharmacology|June 2, 2022
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled TrialsLenard A Adler, Julie Adams, Jessica Madera-McDonough, et al.
Journal of Alzheimer'S Disease : JAD|November 13, 2024
Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer's disease: A 12-week, active-treatment, extension trialSaloni Behl, Mary Slomkowski, Dalei Chen, et al.
Dentistry Journal|February 28, 2020
Pre-Outplacement Perceptions of Dental Students Regarding Rural Oral Health Practice and Associated FactorsMenaka Abuzar, Felicity Crombie, Karin Bishara, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Implementation Research and Practice|April 24, 2023
Augmenting systems-level implementation of patient-reported outcomes for depression care through the use of structured analysis and design techniqueElizabeth J Austin, Joseph A Heim, Savitha Sangameswaran, et al.
Journal of Psychopharmacology (Oxford, England)|March 11, 2021
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar maniaEduard Vieta, Gary Sachs, Denise Chang, et al.
Acta Neuropsychiatrica|November 19, 2024
A randomised study and an extension study of brexpiprazole in patients with borderline personality disorderBrian Rothman, Claudette Brewer, Denise Chang, et al.
Expert Review of Neurotherapeutics|April 1, 2026
Centanafadine for the treatment of attention-deficit/hyperactivity disorder in adults: a plain language summary of publicationCaroline L Ward, Jessica Madera-McDonough, Mary Hobart, et al.
Journal of Clinical Psychopharmacology|July 2, 2025
52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity DisorderGregory W Mattingly, Osman Turkoglu, Denise Chang, et al.
Psychiatric Services (Washington, D.C.)|April 15, 2021
Provision of Collaborative Care Model and General Behavioral Health Integration Services in MedicareLeah M Marcotte, Ashok Reddy, Lingmei Zhou, et al.
Journal of General Internal Medicine|September 2, 2020
Transforming Population-Based Depression Care: a Quality Improvement Initiative Using Remote, Centralized Care ManagementDenise Chang, Andrew D Carlo, Sara Khor, et al.
Journal of Clinical Psychopharmacology|June 2, 2022
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled TrialsLenard A Adler, Julie Adams, Jessica Madera-McDonough, et al.
Journal of Alzheimer'S Disease : JAD|November 13, 2024
Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer's disease: A 12-week, active-treatment, extension trialSaloni Behl, Mary Slomkowski, Dalei Chen, et al.
Dentistry Journal|February 28, 2020
Pre-Outplacement Perceptions of Dental Students Regarding Rural Oral Health Practice and Associated FactorsMenaka Abuzar, Felicity Crombie, Karin Bishara, et al.
Pageof 3